Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 04/16/2014

Company Name Symbol %Change
BITAUTO HOLD BITA
14.82%
ANI PHARMACE ANIP
14.66%
INTERACTIVE IBKR
11.69%
IMMUNOGEN IN IMGN
11.02%
E HOUSECHINA EJ
9.25%
Lowest PEG Ratio in the Health Care Technology Industry Detected for MedAssets (MDAS, OMCL, MDRX)

Print Share

Dec 12, 2012 (Fast Lane via COMTEX) -- Below are the three companies in the Health Care Technology industry with the lowest price to earnings to growth (PEG) ratios. PEG is valuable in assessing the tradeoff between the price of a stock and expected growth. Generally, the lower the PEG, the better.

MedAssets (NASDAQ:MDAS) is lowest with a PEG ratio of 0.92. MedAssets Inc. provides technology-enabled products and services for hospitals and health systems. The Company's technology-enabled solutions are delivered primarily through company-hosted, or ASP-based, software supported by enterprise-wide sales, account management, implementation services and consulting. MedAssets has traded 50,000 shares thus far today, vs. average volume of 417,000 shares per day. The stock has underperformed the Dow (-0.8% to the Dow's 0.1%) and underperformed the S&P 500 (-0.8% to the S&P's 0.2%) during today's trading.

Following is Omnicell (NASDAQ:OMCL) with a PEG ratio of 1.03. Finishing up the bottom three is Allscripts Healthcare Solutions (NASDAQ:MDRX), with a PEG ratio of 1.03. ---------------------------------------------------------------------------------------------

Financial News Network Online (FNNO) is a leading provider of digital financial news content for distribution on the web. You can count on FNNO to bring you the latest market news, earnings reports, analyst comments, economic data reports and more. Visit http://www.fnno.com today.

Copyright, Comtex News Network, Inc. 2012

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.